BASILEA MAINTAINS GLOBAL COMMERCIALIZATION RIGHTS FOR BAL8557

Basilea Pharmaceutica Ltd. (SWX:BSLN) announced today that it maintains global marketing and manufacturing rights to BAL8557 following Roche's decision not to exercise its opt-in right. BAL8557 will be Basilea's third compound to enter phase III clinical development, planned to commence in 2006.

Biotech Intelligence (http://www.biotech-intelligence.com/html/html/3298038f5a9fec2a26d5138326279524.html)